CTOs on the Move

Amarillo Biosciences

www.amarbio.com

 
Amarillo Biosciences, Inc. is a Amarillo, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.amarbio.com
  • 800 SW 9th Ave
    Amarillo, TX USA 79101
  • Phone: 806.376.1741

Executives

Name Title Contact Details

Funding

Amarillo Biosciences raised $20M on 05/03/2021

Similar Companies

Associates of Cape Cod

Associates of Cape Cod is a East Falmouth, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company`s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.

Wheeler Pharmacy

Wheeler Pharmacy is a Lanett, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TLC Laser Eye Centers

TLC Laser Eye Centers is North America’s leading laser eye surgery provider, with more than 20 years of LASIK experience. Book a Free Consultation near you.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.